Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

Financings In Brief

This article was originally published in The Gray Sheet

  • News

Executive Summary

CardioDx raises $58 million for heart test marketing. OmniGuide gets $35 million for surgical laser products. More financings.

You may also be interested in...



News In Brief

CardioNet buys CardioCore Lab. HeartWare gears for HVAD rollout. Zimmer prevails in Genzyme patent case. CardioDx gains Corus CAD heart test Medicare coverage. More news briefs.

New Products In Brief

The latest product approvals and launches in cardiology, orthopedics, diagnostics and more.

CardioDx Launches Gene Test For Obstructive Coronary Disease

CardioDx is gradually rolling out its Corus CAD gene expression test, which quantifies the likelihood of obstructive coronary artery disease in patients with stable chest pain and no previous history of cardiac disease

Table

View full table

Topics

Related Companies

Tags:
Medical Device
Latest Headlines

Medtech Connect Episode 10: Breaking Down The Transitional Coverage Of Emerging Technologies

Medtronic Hires New Neuromodulation Leader

New ePortal To Simplify Processing & Tracking Of WHO Prequalification Applications

Minute Insight: Stimdia Starts Trial Of Phrenic Nerve Stimulator For Patients On Ventilators

See All
UsernamePublicRestriction

Register

MT031518

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By